Biotech Values

[dewophile]

Aasld abstracts are out. Here is a link to late breakers.

https://www.aasld.org/sites/default/files/2022-11/2022%20Late%20Breaking%20Abstracts.pdf

Jnj sirna combo data had no patients achieve primary outcome.

Gsk antisense just under 10 percent got to SVR 24 (functional cure?). Down from 28-29 percent at easl. I would imagine they scrap monotherapy plans for phase 3 (there was a subset with 16 percent SVR). Sequential treatment with interferon data due early next year